# Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

> **NCT02299089** · PHASE2 · COMPLETED · sponsor: **Camurus AB** · enrollment: 12 (actual)

## Conditions studied

- Acromegaly
- Neuroendocrine Tumors

## Interventions

- **DRUG:** octreotide FluidCrystal® injection depot

## Key facts

- **NCT ID:** NCT02299089
- **Lead sponsor:** Camurus AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299089, "Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02299089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*